Ariana Pelosci

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.

William Kennedy, MD, discussed modern radiosurgery techniques, technology selection, and the multidisciplinary approach for treating complex CNS tumors.

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

Race, education, and arm pain were found to influence acupuncture expectancy in patients who are survivors of breast cancer.

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

The study found that older females with central nervous system tumors had significantly lower vigorous physical activity participation vs their counterparts.

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Second interim analysis results from the KEYNOTE-A18 trial show continued efficacy of pembrolizumab/CCRT in those with locally advanced cervical cancer.

Learn how COVID-19 impacted oncology practice from the uptake of telehealth to delays in screening, with key takeaways from leading oncologists.

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

A team from the University of Munich analyzed HRQOL outcomes in rural/urban patients with bladder cancer and after ADT treatment and postoperative radiotherapy in prostate cancer.

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.